文献速递小儿耳鼻咽喉鼻科

标准化尘螨过敏原皮下免疫治疗儿童变应性鼻炎治疗期间的疗效与安全性

[The efficacy and safety of standardized dust mite allergen subcutaneous immunotherapy in children with allergic rhinitis during treatment].
PubMed 文献 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2023-01-01

纳入中南大学湘雅医院耳鼻咽喉头颈外科283例尘螨过敏且完成2~3年皮下免疫治疗(SCIT)的儿童变应性鼻炎患者,总体有效率89.4%(253/283),治疗后各项症状、药物及生活质量评分较基线均显著降低(P值均<0.05);局部不良反应1.67%针次、全身不良反应0.56%针次,多为1级,未出现休克等严重全身不良反应。

要点

  • 283例儿童变应性鼻炎患者SCIT期间总体有效率为89.4%(253/283)。
  • SCIT 2~3年后各项症状、药物及生活质量评分较基线均显著降低(P值均<0.05)。
  • 局部不良反应1.67%针次、全身不良反应0.56%针次,多为1级,未出现休克等严重全身不良反应。

核心结论

  • 标准化尘螨SCIT对儿童变应性鼻炎具有良好的安全性,治疗期间对不同临床特征的儿童患者具有确切疗效,可显著改善各项症状、减少对症药物使用并提高生活质量。

研究设计与样本

  • 纳入2019年8月至2021年10月于中南大学湘雅医院耳鼻咽喉头颈外科就诊、诊断明确为尘螨过敏且完成2~3年SCIT治疗的283例儿童变应性鼻炎患者,其中男性205例、女性78例,平均年龄10.8岁。
  • 记录治疗前及治疗2~3年时的鼻部症状总评分(TNSS)、症状药物总评分(SMS)、鼻结膜炎相关生活质量问卷(RQLQ)和视觉模拟量表(VAS)评分并比较治疗前后差异,同时记录SCIT过程中的不良反应以评价安全性;采用SPSS 22.0软件进行统计学分析。

主要发现

  • 283例儿童变应性鼻炎患者SCIT治疗期间的总体有效率为89.4%(253/283)。
  • 与基线相比,SCIT 2~3年后各项症状评分、药物评分和生活质量评分均显著降低(P值均<0.05)。
  • 不同年龄段、性别、是否吸烟、是否有变应性鼻炎家族史、不同症状严重程度、单一或多重过敏和是否二次免疫治疗的患者均获得良好疗效,组间差异无统计学意义(P值均>0.05)。
  • SCIT期间共注射12 735针次,发生局部不良反应213针次(1.67%),以递增期为主,局部风团直径多为5~20 mm;发生全身不良反应71针次(0.56%),以递增期为主,多为1级反应,未出现休克等严重全身不良反应。

临床怎么用

  • 原文结论认为标准化尘螨SCIT对儿童变应性鼻炎具有良好的安全性和确切疗效,可显著改善症状、减少对症药物使用并提高生活质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of standardized dust mite allergen subcutaneous immunotherapy (SCIT) in children with allergic rhinitis (AR) during treatment. Methods: A total of 283 children with AR diagnosed with definite dust mite allergy and completed 2 to 3 years of SCIT who attended the Department of Otorhinolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, from August 2019 to October 2021 were included, including 205 males and 78 females, with a mean age of 10.8 years. The total nasal symptoms score (TNSS), symptom medication score (SMS), rhinoconjunctivitis quality of life questionnaire (RQLQ) and visual analogue scale (VAS) before and after 2 to 3 years' treatment were recorded, and the differences before and after treatment were compared. Adverse reactions during SCIT were recorded to evaluate its safety. SPSS 22.0 software was used for statistical analysis. Results: The overall effectiveness rate during SCIT in 283 children with AR was 89.4% (253/283). Compared with baseline, all symptom scores, medication scores and quality of life scores were significantly lower after 2 to 3 years of SCIT (all P<0.05). Further group comparisons showed positive efficacy in patients with different clinical characteristics, including age, gender, smoking status, family history of AR, symptom severity, mono-or poly-allergy, and second immunization, with no statistically significant differences between groups (all P>0.05). A total of 12 735 injections were administered during the SCIT, and a total of 213 (1.67%) injections of local adverse reactions occurred, mainly in the initial treatment phase, and the diameter of the local air mass was mostly 5 to 20 mm; 71 (0.56%) injections of systemic adverse reactions occurred, mainly in the initial treatment phase, and most of them were grade 1 reactions with no serious systemic adverse reaction such as shock. Conclusion: Standardized dust mite SCIT has a good safety profile and definite efficacy in treating AR children with different clinical characteristics. It can significantly improve all symptoms, reduce the use of symptomatic drugs and improve their quality of life. 目的: 评估标准化尘螨过敏原皮下免疫治疗(subcutaneous immunotherapy,SCIT)对儿童变应性鼻炎(AR)患者治疗期间的疗效和安全性。 方法: 纳入2019年8月至2021年10月于中南大学湘雅医院耳鼻咽喉头颈外科就诊的283例诊断明确为尘螨过敏且完成2~3年SCIT治疗的儿童AR患者,其中男性205例,女性78例,平均年龄10.8岁。记录治疗前及治疗2~3年时不同临床特征儿童AR患者的鼻部症状总评分(total nasal symptoms scores,TNSS)、症状药物总评分(symptom medication score,SMS)、鼻结膜炎相关生活质量评分(rhinoconjunctivitis quality of life questionnaire,RQLQ)和视觉模拟量表(VAS)评分,并比较治疗前后的差异。记录SCIT过程中的不良反应,以评价其安全性。采用SPSS 22.0软件进行统计学分析。 结果: 283例儿童AR患者SCIT治疗期间的总体有效率为89.4%(253/283)。与基线相比,SCIT 2~3年后儿童AR患者的各项症状评分、药物评分和生活质量评分均显著降低(P值均<0.05)。进一步对不同临床特征的儿童AR患者进行分组比较,发现不同年龄段、性别、是否吸烟、是否有AR家族史、不同症状严重程度、单一或多重过敏和是否二次免疫治疗的儿童AR患者均获得良好疗效,且组间差异无统计学意义(P值均>0.05)。SCIT期间共注射12 735针次,共发生213(1.67%)针次局部不良反应,以递增期为主,局部风团直径多为5~20 mm;共发生71(0.56%)针次全身不良反应,以递增期为主,多为1级反应,未出现休克等严重全身不良反应。 结论: 标准化尘螨SCIT具有良好的安全性,治疗期间对不同临床特征的儿童AR患者具有确切疗效,可显著改善患儿各项症状,减少对症药物使用,并提高生活质量。.

来源:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yuan X, Xie SB, Zhang H, et al. [The efficacy and safety of standardized dust mite allergen subcutaneous immunotherapy in children with allergic rhinitis during treatment]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023. PMID: 37675526. doi:10.3760/cma.j.cn115330-20230331-00146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。